SCHEMBL25201864

SCHEMBL25201864

[CH2]C(=O)c1ccncc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 4/20 0.42
TDP1 Q9NUW8 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
MEN1 O00255 1/20 0.42
KDM6B O15054 1/20 0.42
KDM4A O75164 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
KMT2A Q03164 1/20 0.42
KDM4D Q6B0I6 1/20 0.42
SIRT3 Q9NTG7 2/20 0.41
LOXL2 Q9Y4K0 1/20 0.39
ABL1 P00519 1/20 0.39
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
ORAI1 Q96D31 3/20 0.36
STIM1 Q13586 2/20 0.36
TRPC1 P48995 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29578794 0.81 KDM4C (0.59) KDM4CTDP1KDM4EALDH1A1L3MBTL1
SCHEMBL82604 0.81 KDM4C (0.59) KDM4CTDP1KDM4EALDH1A1L3MBTL1
SCHEMBL459712 0.79 LOXL2 (0.44) KDM4CTDP1KDM4EALDH1A1L3MBTL1
SCHEMBL724581 0.79 ALDH1A1 (0.52) KDM4CTDP1KDM4EALDH1A1L3MBTL1
Hydrochloric Acid SCHEMBL1027857 0.79 KDM4C (0.57) KDM4CTDP1KDM4EALDH1A1L3MBTL1
SCHEMBL2618803 0.79 TDP1 (0.55) KDM4CTDP1KDM4EALDH1A1L3MBTL1
SCHEMBL30298673 0.79 TDP1 (0.55) KDM4CTDP1KDM4EALDH1A1L3MBTL1
SCHEMBL30475729 0.77 KDM4C (0.42) KDM4CTDP1KDM4EALDH1A1L3MBTL1
SCHEMBL17425264 0.77 LOXL2 (0.41) KDM4CTDP1KDM4EALDH1A1L3MBTL1
SCHEMBL19273667 0.75 LOXL2 (0.39) KDM4CTDP1KDM4EALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295157-A1 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS JANSSEN RESEARCH & DEVELOPMENT, LLC 2023-09-21 US disclosed
EP-4185588-A1 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS Janssen Pharmaceutica NV (BE) 2023-05-31 EP disclosed
CN-116134035-A 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors 詹森药业有限公司 2023-05-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295157-A1 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS SERPINC1, F11, TFPI2 KDM4C 1694/4885TDP1 1930/4885KDM4E 1528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.